China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 14.35 billion. The enterprise value is 13.10 billion.
| Market Cap | 14.35B |
| Enterprise Value | 13.10B |
Important Dates
The next estimated earnings date is Saturday, March 28, 2026.
| Earnings Date | Mar 28, 2026 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
Guobang Pharma has 552.99 million shares outstanding. The number of shares has decreased by -0.21% in one year.
| Current Share Class | 552.99M |
| Shares Outstanding | 552.99M |
| Shares Change (YoY) | -0.21% |
| Shares Change (QoQ) | +0.95% |
| Owned by Insiders (%) | 12.79% |
| Owned by Institutions (%) | 11.86% |
| Float | 224.74M |
Valuation Ratios
The trailing PE ratio is 16.54 and the forward PE ratio is 15.51.
| PE Ratio | 16.54 |
| Forward PE | 15.51 |
| PS Ratio | 2.41 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | 24.03 |
| P/OCF Ratio | 13.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.31, with an EV/FCF ratio of 21.95.
| EV / Earnings | 15.01 |
| EV / Sales | 2.21 |
| EV / EBITDA | 9.31 |
| EV / EBIT | 14.71 |
| EV / FCF | 21.95 |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.20 |
| Quick Ratio | 2.03 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.68 |
| Debt / FCF | 1.60 |
| Interest Coverage | 39.25 |
Financial Efficiency
Return on equity (ROE) is 10.79% and return on invested capital (ROIC) is 11.23%.
| Return on Equity (ROE) | 10.79% |
| Return on Assets (ROA) | 5.25% |
| Return on Invested Capital (ROIC) | 11.23% |
| Return on Capital Employed (ROCE) | 10.14% |
| Weighted Average Cost of Capital (WACC) | 5.83% |
| Revenue Per Employee | 1.48M |
| Profits Per Employee | 218,075 |
| Employee Count | 4,003 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.04 |
Taxes
In the past 12 months, Guobang Pharma has paid 128.39 million in taxes.
| Income Tax | 128.39M |
| Effective Tax Rate | 12.86% |
Stock Price Statistics
The stock price has increased by +25.42% in the last 52 weeks. The beta is 0.33, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +25.42% |
| 50-Day Moving Average | 24.59 |
| 200-Day Moving Average | 22.30 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 5,128,362 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 5.94 billion and earned 872.95 million in profits. Earnings per share was 1.57.
| Revenue | 5.94B |
| Gross Profit | 1.48B |
| Operating Income | 890.91M |
| Pretax Income | 998.22M |
| Net Income | 872.95M |
| EBITDA | 1.41B |
| EBIT | 890.91M |
| Earnings Per Share (EPS) | 1.57 |
Balance Sheet
The company has 2.21 billion in cash and 958.11 million in debt, with a net cash position of 1.25 billion or 2.26 per share.
| Cash & Cash Equivalents | 2.21B |
| Total Debt | 958.11M |
| Net Cash | 1.25B |
| Net Cash Per Share | 2.26 |
| Equity (Book Value) | 8.28B |
| Book Value Per Share | 15.02 |
| Working Capital | 3.96B |
Cash Flow
In the last 12 months, operating cash flow was 1.08 billion and capital expenditures -481.97 million, giving a free cash flow of 597.08 million.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -481.97M |
| Free Cash Flow | 597.08M |
| FCF Per Share | 1.08 |
Margins
Gross margin is 24.93%, with operating and profit margins of 14.99% and 14.69%.
| Gross Margin | 24.93% |
| Operating Margin | 14.99% |
| Pretax Margin | 16.80% |
| Profit Margin | 14.69% |
| EBITDA Margin | 23.69% |
| EBIT Margin | 14.99% |
| FCF Margin | 10.05% |
Dividends & Yields
This stock pays an annual dividend of 0.61, which amounts to a dividend yield of 2.33%.
| Dividend Per Share | 0.61 |
| Dividend Yield | 2.33% |
| Dividend Growth (YoY) | 100.92% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 40.77% |
| Buyback Yield | 0.21% |
| Shareholder Yield | 2.42% |
| Earnings Yield | 6.08% |
| FCF Yield | 4.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Guobang Pharma has an Altman Z-Score of 4.84 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.84 |
| Piotroski F-Score | 7 |